Bidirectional Mendelian randomization uncovers link between plasma metabolites and heart attack risk

Myocardial infarction, more commonly known as a heart attack, is a leading cause of death worldwide. Biomarkers called plasma metabolites may play a key role in the physiological pathways involved in myocardial infarctions.

Incyte acquires global rights to MorphoSys’ tafasitamab

Share this article A CD19-targeting immunotherapy, tafasitamab is approved as a combination regimen to treat B-cell lymphoma. Credit: CI Photos / Shutterstock.com. Incyte has acquired

February 6, 2024

RFK Jr. Wants Access to Federal Data to Show Vaccines Are Unsafe, Trump Advisor Says

A co-chair of Donald Trump’s transition team said Trump supporter Robert F. Kennedy Jr. wants access to federal health data so he can show vaccines

November 2, 2024

Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma

Elotuzumab (Empliciti) failed for a third time to improve progression-free survival (PFS) in newly diagnosed multiple myeloma when added to standard therapy, a large randomized

February 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.